Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first‐line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires resistance to sunitinib, rendering it difficult to treat with this a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Kuroshima, Kazuki, Yoshino, Hirofumi, Okamura, Shunsuke, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226215/
https://ncbi.nlm.nih.gov/pubmed/32232883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14395
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge